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Background: Data from clinical trials have demonstrated that patients with acute coronary syndrome (ACS) and non-obstructive coronary artery 
disease (CAD) detected by angiography have a substantial risk of subsequent coronary events within one-year. However, the prognosis of these 
patients in the real world setting has been poorly investigated. The aim of this study was to evaluate the long-term outcome of patients with ACS 
presenting with non-obstructive CAD and the rate of prescription at discharge of aspirin and clopidogrel according to guideline recommendations.
Methods: ACS patients presenting at our Institution and undergoing coronary angiography were screened. ACS was defined according to ACC/AHA 
criteria. Non-obstructive CAD was defined as angiographic findings of <50% diameter stenosis in any major epicardial artery. These patients were 
further stratified into 2 groups according to their angiographic findings: Group A (0% stenosis) and Group B (>0% and <50% stenosis). Patients were 
followed-up for 2 years. Major adverse cardiac events (MACE), defined as death, ACS leading to hospitalization, and non-fatal stroke were recorded.
Results: A total of 2157 ACS patients were screened, of whom 261 (12%) presented non-obstructive CAD defined according to study criteria. 
Groups A and B were composed of 123 (47.1%) and 138 (52.9%) patients, respectively. The overall MACE rate at 2 years was 6.5%, with a numerical 
increase, albeit not statistically significant among group B versus group A patients (9.2% vs 3.3%, p = 0.20). During follow-up, group B patients were 
more frequently hospitalized for ACS and underwent coronary revascularization compared with group A patients (7.0% vs 1.1%, p = 0.04). Despite 
guideline recommendations, only 49% of patients with ACS and non-obstructive CAD were prescribed with dual antiplatelet therapy. Patients on 
aspirin or clopidogrel alone were 87% and 54%, respectively.
Conclusions: ACS patients with non-obstructive CAD have a low use of dual antiplatelet therapy and remain at high risk for long-term recurrent 
ischemic events, underscoring the need for aggressive medical management in these patients.
